Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Crispr Therapeutics Ag (CRSP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,341,796
  • Shares Outstanding, K 52,910
  • Annual Sales, $ 3,120 K
  • Annual Income, $ -164,980 K
  • 60-Month Beta 2.96
  • Price/Sales 749.61
  • Price/Cash Flow N/A
  • Price/Book 6.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.85
  • Number of Estimates 6
  • High Estimate -0.52
  • Low Estimate -1.01
  • Prior Year -0.82
  • Growth Rate Est. (year over year) -3.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.05 +23.45%
on 06/03/19
45.35 -4.59%
on 06/11/19
+5.65 (+15.02%)
since 05/14/19
3-Month
33.55 +28.97%
on 03/25/19
45.35 -4.59%
on 06/11/19
+4.72 (+12.24%)
since 03/14/19
52-Week
22.22 +94.73%
on 12/21/18
66.72 -35.15%
on 06/21/18
-15.79 (-26.74%)
since 06/14/18

Most Recent Stories

More News
Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash

Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

CELG : 96.51 (+0.07%)
CRSP : 43.27 (-2.24%)
VRTX : 170.22 (+0.79%)
CBAY : 6.28 (-6.96%)
INSY : 0.34 (-15.00%)
BIIB : 227.67 (-1.55%)
CRISPR Therapeutics Up on Collaboration Expansion by Vertex

CRISPR Therapeutics (CRSP) is set to receive $175 million in upfront payment from Vertex following the expansion of the collaboration agreement for gene editing program to include new disease areas.

BAYRY : 14.8300 (-1.53%)
CRSP : 43.27 (-2.24%)
VRTX : 170.22 (+0.79%)
EDIT : 21.73 (-3.47%)
Vertex Selects Triple Combo Regimen for Regulatory Submission

Vertex (VRTX) choses VX-445 triple combination regimen for global regulatory submissions to seek approval for the regimen as a treatment for cystic fibrosis based on 24-week phase III study data.

CRSP : 43.27 (-2.24%)
PTI : 1.00 (-0.99%)
VRTX : 170.22 (+0.79%)
ABBV : 78.69 (-0.33%)
CRISPR Therapeutics to Present at Upcoming Investor Conferences

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive...

CRSP : 43.27 (-2.24%)
Vertex (VRTX) Q1 Earnings and Revenues Surpass Estimates

Vertex (VRTX) beats on both earnings and sales in Q1 with demand for its newest CF drug, Symdeko, rising high.

CRSP : 43.27 (-2.24%)
PDLI : 2.91 (-2.35%)
MRUS : 13.40 (+0.68%)
VRTX : 170.22 (+0.79%)
CRISPR Therapeutics to Participate in Upcoming Investor Conferences

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team...

CRSP : 43.27 (-2.24%)
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results

-Enrollment ongoing in Phase 1/2 clinical trials of CTX001(TM) for patients with severe hemoglobinopathies-

CRSP : 43.27 (-2.24%)
What's in Store for Vertex (VRTX) This Earnings Season?

On Vertex's (VRTX) first-quarter earnings call, investor focus will be on its latest CF drug Symdeko's sales figure as well as the update on its CF triple-pill regimes.

CRSP : 43.27 (-2.24%)
VRTX : 170.22 (+0.79%)
INCY : 77.71 (+1.75%)
ADRO : 1.79 (-3.76%)
Analysis: Positioning to Benefit within CRISPR Therapeutics AG, SPIRIT MTA REIT, Gaia, Perceptron, Check-Cap, and Key Tronic -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CRISPR Therapeutics AG (NASDAQ:CRSP),...

SMTA : 8.61 (+0.23%)
CRSP : 43.27 (-2.24%)
GAIA : 7.29 (-1.62%)
CHEK : 2.34 (-1.55%)
PRCP : 4.46 (-0.44%)
KTCC : 5.08 (+0.20%)
Vertex, CRISPR's Gene Editing Drug Gets FDA's Fast Track Tag

FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for a second indication - transfusion-dependent beta thalassemia.

CRSP : 43.27 (-2.24%)
VRTX : 170.22 (+0.79%)
EDIT : 21.73 (-3.47%)
NTLA : 13.90 (-3.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade CRSP with:

Business Summary

CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.

See More

Key Turning Points

2nd Resistance Point 44.97
1st Resistance Point 44.12
Last Price 43.27
1st Support Level 42.64
2nd Support Level 42.01

See More

52-Week High 66.72
Fibonacci 61.8% 49.72
Fibonacci 50% 44.47
Last Price 43.27
Fibonacci 38.2% 39.22
52-Week Low 22.22

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar